These tables show the top 10 subsidised drugs for the year July 2011 – June 2012.
Table 3 Top 10 drugs by cost to government †
Drug
|
Cost to government (A$)
|
DDD/1000 pop/day* PBS/RPBS ‡
|
Prescriptions PBS/RPBS ‡
|
1. atorvastatin
|
606 051 755
|
82.99
|
10 855 535
|
2. rosuvastatin
|
369 088 997
|
38.14
|
7 035 996
|
3. ranibizumab
|
367 753 306
|
§
|
172 785
|
4. adalimumab
|
205 117 624
|
0.39
|
115 277
|
5. esomeprazole
|
178 922 823
|
21.91
|
6 069 831
|
6. salmeterol and fluticasone
|
177 315 166
|
¶
|
3 130 577
|
7. olanzapine
|
159 400 059
|
3.05
|
965 797
|
8. clopidogrel
|
139 521 901
|
11.00
|
2 635 142
|
9. etanercept
|
131 116 800
|
0.26
|
74 605
|
10. rituximab
|
129 299 223
|
§
|
59 284
|
* The defined daily dose (DDD)/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. (For WHO definition of DDD see www.whocc.no/ddd/definition_and_general_considera/)
† Based on date of supply. Does not include private prescriptions or prescriptions under PBS co-payment.
‡ PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme
§ The World Health Organization has not allocated a DDD for this drug
¶ This combination does not have a DDD allocated Source: Drug Utilisation Sub-Committee (DUSC) Database, as at 3 October 2012. © Commonwealth of Australia.
Data are based on date of supply with processing date up to the month of September 2012. Data exclude 'Under co-payment' and 'Closing the gap' prescriptions processed by the Department of Human Services.